Literature DB >> 3197366

Phenytoin pharmacokinetics in critically ill trauma patients.

B A Boucher1, J H Rodman, G S Jaresko, S N Rasmussen, C B Watridge, T C Fabian.   

Abstract

Preliminary data have suggested that phenytoin systemic clearance may increase during initial therapy in critically ill patients. The objectives for this study were to model the time-variant phenytoin clearance and evaluate concomitant changes in protein binding and urinary metabolite elimination. Phenytoin was given as an intravenous loading dose of 15 mg/kg followed by an initial maintenance dose of 6 mg/kg/day in 10 adult critically ill trauma patients. Phenytoin bound and unbound plasma concentrations were determined in 10 patients and urinary excretion of the metabolite p-hydroxyphenyl phenylhydantoin (p-HPPH) was measured in seven patients for 7 to 14 days. A Michaelis-Menten one-compartment model incorporating a time-variant maximal velocity (Vmax) was sufficient to describe the data and superior to a conventional time-invariant Michaelis-Menten model. Vmax for the time-variant model was defined as V'max + Vmax delta (1 - e(-kindt)). Vmax infinity is the value for Vmax when t is large. The median values (ranges) for the parameters were Km = 4.8 (2.6 to 20) mg/L, Vmax infinity = 1348 (372 to 4741) mg/day, and kind = 0.0115 (0.0045 to 0.132) hr-1. Phenytoin free fraction increased in a majority of patients during the study period, with a binding ratio inversely related to albumin. Measured urinary p-HPPH data were consistent with the proposed model. A loading and constant maintenance dose of phenytoin frequently yielded a substantial, clinically significant fall in plasma concentrations with a pattern of apparently increasing clearance that may be a consequence of changes in protein binding, induction of metabolism, or the influence of stress on hepatic metabolic capacity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197366     DOI: 10.1038/clpt.1988.211

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.

Authors:  Gail D Anderson; Nancy R Temkin; Asaad B Awan; H Richard Winn; Richard H Winn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.

Authors:  G D Anderson; A B Awan; C A Adams; N R Temkin; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

5.  Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model.

Authors:  Gail D Anderson; Todd C Peterson; Cole Vonder Haar; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Michael R Hoane
Journal:  AAPS J       Date:  2015-06-12       Impact factor: 4.009

Review 6.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

7.  Decreased plasma protein binding of valproate in patients with acute head trauma.

Authors:  G D Anderson; B E Gidal; R J Hendryx; A B Awan; N R Temkin; A J Wilensky; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

9.  Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series.

Authors:  Deborah A Pasko; Mariann D Churchwell; Imad F Btaiche; Jinesh C Jain; Bruce A Mueller
Journal:  Pediatr Nephrol       Date:  2009-01-21       Impact factor: 3.714

10.  IV fosphenytoin in obese patients: Dosing strategies, safety, and efficacy.

Authors:  Sarah L Clark; Megan R Leloux; Ross A Dierkhising; Gregory D Cascino; Sara E Hocker
Journal:  Neurol Clin Pract       Date:  2017-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.